AP3B1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL4699140	0.80	2/20
SCHEMBL4922941	0.80	2/20
SCHEMBL4916509	0.78	2/20
SCHEMBL4700123	0.77	2/20
SCHEMBL4698636	0.76	2/20
SCHEMBL4914334	0.76	2/20
SCHEMBL4917606	0.76	2/20
SCHEMBL4908396	0.74	2/20
SCHEMBL4699183	0.74	2/20
SCHEMBL4914310	0.73	2/20
SCHEMBL4915098	0.73	2/20
SCHEMBL4696222	0.72	2/20
SCHEMBL4701699	0.70	2/20
SCHEMBL4698169	0.70	2/20
SCHEMBL4696537	0.68	2/20
SCHEMBL4920392	0.66	2/20

Clinical trials — most relevant to AP3B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy	PHASE4	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)	PHASE1/PHASE2	NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy	EARLY_PHASE1	RECRUITING
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases	nan	RECRUITING
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome	nan	RECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Identification of Acute Intermittent Porphyria Modifying Genes	nan	RECRUITING
Biomarkers of CASH	nan	ACTIVE_NOT_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS	nan	NOT_YET_RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)	nan	COMPLETED
Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN
AutoInflammatory Disease Alliance Registry (AIDA)	nan	RECRUITING
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a AP3B1 binder may also engage these)

Protein	Name	Similarity
Q7YRF1	—	1.000	Q7YRF1 →
Q9Z1T1	—	1.000	Q9Z1T1 →
Q32PG1	—	1.000	Q32PG1 →
Q13367	—	0.997	Q13367 →
Q9JME5	—	0.995	Q9JME5 →
Q9QZE5	—	0.991	Q9QZE5 →
Q8L7A9	—	0.991	Q8L7A9 →
Q9I8E6	—	0.991	Q9I8E6 →
Q66JI9	—	0.990	Q66JI9 →
COPG1	Coatomer subunit gamma-1	0.990	landscape →
O54774	—	0.990	O54774 →
Q9QXK3	—	0.990	Q9QXK3 →
Q9PUE4	—	0.990	Q9PUE4 →
Q0WW26	—	0.989	Q0WW26 →
P53620	—	0.989	P53620 →
COPG2	Coatomer subunit gamma-2	0.988	landscape →
Q8I0G5	—	0.988	Q8I0G5 →
Q54X82	—	0.988	Q54X82 →
Q6DKD7	—	0.988	Q6DKD7 →
O13046	—	0.988	O13046 →
Q8RW96	—	0.987	Q8RW96 →
A6N6J5	—	0.987	A6N6J5 →
AP3D1	AP-3 complex subunit delta-1	0.987	landscape →
Q6Z382	—	0.987	Q6Z382 →
Q9ZUI6	—	0.986	Q9ZUI6 →
Q84K16	—	0.986	Q84K16 →
Q5ZL91	—	0.986	Q5ZL91 →
P22892	—	0.986	P22892 →
Q7ZX60	—	0.985	Q7ZX60 →
Q07205	—	0.985	Q07205 →